دورية أكاديمية
أعرض في EDS

Molecular imaging to support cancer immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Molecular imaging to support cancer immunotherapy.
المؤلفون: van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Knapen DG; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van der Wekken AJ; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Lub-de Hooge MN; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., de Vries EG; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands e.g.e.de.vries@umcg.nl.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Aug; Vol. 10 (8).
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Immunotherapy*/methods , Neoplasms*/drug therapy , Neoplasms*/therapy, Antibodies, Monoclonal/therapeutic use ; Humans ; Molecular Imaging ; Positron-Emission Tomography/methods
مستخلص: The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patients across several tumor types. However, not all patients respond to immunotherapy therefore predictive biomarkers are important. There are only a few Food and Drug Administration-approved biomarkers to select patients for immunotherapy. These biomarkers do not consider the heterogeneity of tumor characteristics across lesions within a patient. New molecular imaging tracers allow for whole-body visualization with positron emission tomography (PET) of tumor and immune cell characteristics, and drug distribution, which might guide treatment decision making. Here, we summarize recent developments in molecular imaging of immune checkpoint molecules, such as PD-L1, PD-1, CTLA-4, and LAG-3. We discuss several molecular imaging approaches of immune cell subsets and briefly summarize the role of FDG-PET for evaluating cancer immunotherapy. The main focus is on developments in clinical molecular imaging studies, next to preclinical studies of interest given their potential translation to the clinic.
Competing Interests: Competing interests: EDV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (paid to UMCG). AvdW reports an advisory role at Janssen, Takeda, and Boehringer-Ingelheim (paid to UMCG) and research funding from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche, and Takeda. ML-dH reports research funding from Merck, Bayer, and Amgen (paid to UMCG). SO reports research funding from Novartis, Pfizer and Celldex Therapeutics (paid to UMCG) and an advisory role at Bristol Myers Squibb (paid to the UMCG).
(© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: AAPS J. 2020 Jan 3;22(2):22. (PMID: 31900688)
J Nucl Med. 2022 Oct;63(10):1523-1530. (PMID: 35512998)
J Nucl Med. 2020 Apr;61(4):512-519. (PMID: 31586002)
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. (PMID: 28828507)
Cancer Cell. 2021 Jan 11;39(1):122. (PMID: 33306984)
Eur J Cancer. 2018 Sep;101:181-190. (PMID: 30077123)
J Immunol. 2021 Sep 1;207(5):1468-1477. (PMID: 34408009)
J Nucl Med. 2015 Aug;56(8):1258-64. (PMID: 25952734)
Mol Imaging. 2019 Jan-Dec;18:1536012119829986. (PMID: 31044647)
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. (PMID: 28512174)
Clin Cancer Res. 2009 Jan 1;15(1):390-9. (PMID: 19118070)
Clin Cancer Res. 2021 Aug 1;27(15):4195-4204. (PMID: 33753453)
Cancer Res. 2017 May 1;77(9):2318-2327. (PMID: 28461564)
N Engl J Med. 2022 Apr 7;386(14):1297-1301. (PMID: 34910860)
ACS Cent Sci. 2021 Oct 27;7(10):1638-1649. (PMID: 34729407)
J Nucl Med. 2022 May;63(5):686-693. (PMID: 34385342)
N Engl J Med. 2018 Aug 30;379(9):e14. (PMID: 30157404)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34301816)
J Nucl Med. 2022 Mar;63(3):362-367. (PMID: 34272316)
Nat Commun. 2021 Feb 16;12(1):1047. (PMID: 33594075)
Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375)
J Exp Med. 2006 Apr 17;203(4):883-95. (PMID: 16606670)
Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526)
Leuk Lymphoma. 2019 Feb;60(2):367-375. (PMID: 30032683)
J Nucl Med. 2018 Jun;59(6):980-985. (PMID: 29326360)
Oncotarget. 2018 Jul 13;9(54):30268-30278. (PMID: 30100988)
Mol Oncol. 2014 Sep 12;8(6):1095-111. (PMID: 25087573)
Mol Imaging Biol. 2020 Oct;22(5):1392-1402. (PMID: 32705455)
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7. (PMID: 27333363)
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4369-4376. (PMID: 34076745)
Nat Med. 2019 Mar;25(3):470-476. (PMID: 30742120)
Eur J Cancer. 2021 Jul;151:72-83. (PMID: 33971447)
J Immunother Cancer. 2019 Oct 26;7(1):278. (PMID: 31655605)
Nat Med. 2020 Dec;26(12):1845-1851. (PMID: 33046869)
Mol Imaging Biol. 2021 Oct;23(5):714-723. (PMID: 33713000)
J Nucl Med. 2019 Mar;60(3):335-341. (PMID: 30413661)
Cancer Immunol Res. 2016 Mar;4(3):194-203. (PMID: 26787823)
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2068-2080. (PMID: 36859619)
Nat Commun. 2018 Nov 7;9(1):4664. (PMID: 30405135)
Clin Cancer Res. 2021 Apr 1;27(7):1932-1940. (PMID: 33408249)
Nucl Med Commun. 2019 Aug;40(8):802-807. (PMID: 31045745)
Cancer Discov. 2016 Aug;6(8):827-37. (PMID: 27301722)
EJNMMI Res. 2019 Jan 29;9(1):8. (PMID: 30694399)
J Immunother Cancer. 2020 May;8(1):. (PMID: 32461343)
Lancet Oncol. 2020 Nov;21(11):1413-1422. (PMID: 32979984)
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. (PMID: 27251642)
J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34135101)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
Front Immunol. 2021 Dec 09;12:799910. (PMID: 34956237)
J Immunother Cancer. 2022 Sep;10(9):. (PMID: 36137649)
Int J Mol Sci. 2021 May 17;22(10):. (PMID: 34067904)
Clin Cancer Res. 2020 Jul 1;26(13):3211-3219. (PMID: 32269052)
JAMA Netw Open. 2019 May 3;2(5):e192535. (PMID: 31050774)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. (PMID: 29478079)
Nat Med. 2020 Apr;26(4):566-576. (PMID: 32251400)
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. (PMID: 29124281)
Adv Ther (Weinh). 2020 Jul;3(7):. (PMID: 33889713)
N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797)
Theranostics. 2019 Oct 18;9(26):8221-8238. (PMID: 31754392)
Iowa Orthop J. 2006;26:154-8. (PMID: 16789469)
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. (PMID: 32665297)
Ann Oncol. 2022 Jan;33(1):80-88. (PMID: 34736925)
Mucosal Immunol. 2018 May;11(3):932-946. (PMID: 29346349)
Nat Med. 2019 Mar;25(3):454-461. (PMID: 30804515)
Pharmaceutics. 2022 Jan 08;14(1):. (PMID: 35057046)
Int J Mol Sci. 2020 Dec 23;22(1):. (PMID: 33374804)
Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909)
Clin Cancer Res. 2021 Oct 1;27(19):5325-5333. (PMID: 34253583)
J Clin Med. 2020 Mar 07;9(3):. (PMID: 32156047)
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. (PMID: 30787022)
Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. (PMID: 30777877)
Ann Oncol. 2022 Jan;33(1):99-106. (PMID: 34687894)
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):428-448. (PMID: 32728798)
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. (PMID: 31214790)
J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276. (PMID: 30718052)
Nat Med. 2018 Dec;24(12):1852-1858. (PMID: 30478423)
JAMA Oncol. 2020 Oct 1;6(10):1563-1570. (PMID: 32852531)
J Thorac Oncol. 2020 May;15(5):816-826. (PMID: 32036071)
Ann Oncol. 2018 Oct 1;29(10):2115-2120. (PMID: 30137228)
Mol Imaging Biol. 2017 Aug;19(4):599-609. (PMID: 27966069)
Cancer Res. 2019 Jul 1;79(13):3455-3465. (PMID: 31064845)
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075. (PMID: 29532102)
Clin Cancer Res. 2020 Aug 1;26(15):3999-4009. (PMID: 31953313)
J Nucl Med. 2022 Apr;63(4):536-542. (PMID: 34326125)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
AAPS J. 2021 Mar 7;23(2):39. (PMID: 33677681)
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. (PMID: 29599411)
Sci Rep. 2019 Sep 16;9(1):13362. (PMID: 31527660)
J Nucl Med. 2022 Jun;63(6):899-905. (PMID: 34503964)
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157. (PMID: 31754795)
J Nucl Med. 2022 May;63(5):720-726. (PMID: 34413145)
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2584-2594. (PMID: 35037984)
Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. (PMID: 30617133)
Clin Cancer Res. 2019 Feb 15;25(4):1196-1205. (PMID: 30327313)
JAMA Oncol. 2019 Nov 01;5(11):1614-1618. (PMID: 31436822)
Cancer Res. 2017 Jun 1;77(11):2893-2902. (PMID: 28572504)
Pharmacol Ther. 1994;64(3):529-64. (PMID: 7724661)
Nat Commun. 2016 Aug 30;7:12624. (PMID: 27571927)
Molecules. 2020 Jul 07;25(13):. (PMID: 32646038)
فهرسة مساهمة: Keywords: immunotherapy; review; tumor biomarkers
المشرفين على المادة: 0 (Antibodies, Monoclonal)
تواريخ الأحداث: Date Created: 20220803 Date Completed: 20220805 Latest Revision: 20240902
رمز التحديث: 20240902
مُعرف محوري في PubMed: PMC9352987
DOI: 10.1136/jitc-2022-004949
PMID: 35922089
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2022-004949